Warm Congratulations to EClinCloud Partner Trinomab on Its Successful Listing on the STAR Market

Source: EClinCloud. Author: EClinCloud.
Warm
Congratulations
On July 21, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. (stock abbreviation: Trinomab; stock code: 688806) was officially listed on the Shanghai Stock Exchange STAR Market, entering a new stage of capitalization and high-quality development.
As a long-term partner of Trinomab, EClinCloud extends its warm congratulations to Trinomab on its successful listing on the STAR Market.
The two parties have long conducted in-depth collaboration on clinical research for innovative drugs. EClinCloud has consistently provided Trinomab with integrated solutions including eCOA and end-to-end service support, helping the research team achieve high-quality clinical data collection and management and providing solid digital support for innovative drug R&D.
Going forward, EClinCloud will continue working hand in hand with Trinomab, leveraging digital and AI technological capabilities to jointly explore innovative practices in clinical research and advance new drug R&D to benefit more patients!
The following content is reprinted from: Official WeChat Account of Zhuhai Trinomab Pharmaceutical Co., Ltd.

Trinomab's first commercialized core flagship product—the next-generation "tetanus shot" Siltartoxatug Injection (brand name: Xintituo)—offers rapid onset, a complete protection period, and potent neutralization of tetanus toxin without requiring a skin test. It is the world's first (First-in-Class) fully human anti-tetanus monoclonal antibody and the first domestic innovative biologic in the anti-infective field to receive Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The emergence of this anti-tetanus monoclonal antibody has broken the century-long dependence on blood-derived products for tetanus passive immunization.
Trinomab is committed to alternative therapies for blood-derived products. Leveraging proprietary technology platforms such as its independently developed "HitmAb high-throughput integrated technology platform for fully human monoclonal antibody R&D," the company continues to explore the potential for higher safety and efficacy of antibody drugs in the fully human monoclonal antibody field, and has successfully developed multiple antibody molecules as drug candidates covering disease areas such as infectious diseases and pain-related conditions.
In addition to its commercialized anti-tetanus monoclonal antibody, Siltartoxatug Injection, which underpins its core business performance, Trinomab's multi-tiered, deep R&D pipeline provides a second growth curve for long-term value creation. For another core product, the recombinant long-acting fully human anti-respiratory syncytial virus (RSV) monoclonal antibody Ruiteweibai Monoclonal Antibody Injection (芮特韦拜单抗注射液, formerly TNM001), its New Drug Application (NDA) has been accepted and included in the Priority Review procedure, and the program has been selected as a National Science and Technology Major Project—backed by national strategy and dedicated to independent innovative R&D to overcome key challenges in infant and young child RSV protection. Its Phase III clinical study results showed that a single intramuscular injection significantly reduced the incidence of RSV-induced lower respiratory tract infection in healthy term and late preterm infants, providing sustained protection for up to 270 days post-injection—far exceeding a typical 150-day RSV epidemic season. In addition, the anti-nerve growth factor monoclonal antibody TNM009 and the anti-varicella-zoster virus monoclonal antibody TNM005 have completed Phase I clinical trials, and 3 other drug candidates are in the preclinical stage.
From uncharted territory where no global recombinant anti-tetanus monoclonal antibody had yet ventured to today's milestone listing on the STAR Market, a decade of dedicated work represents an innovation marathon in service of patients. Standing at a new capital starting point, Trinomab will continue to unlock innovative value, bringing cutting-edge biopharmaceutical technologies out of the laboratory and translating them into accessible, high-quality therapies that tangibly benefit patients.

EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products such as eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, along with scale management, linguistic validation, rater training, and data quality analysis services to establish efficient and precise digital solutions. Relying on AI prediction models and an intelligent data platform, it dynamically assesses and helps improve the success rate of drug clinical trials, helping shorten drug/device R&D cycles and benefit patients.



